Compare TURB & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TURB | CTXR |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5M | 18.9M |
| IPO Year | 2023 | 2010 |
| Metric | TURB | CTXR |
|---|---|---|
| Price | $1.51 | $0.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 403.1K | 243.2K |
| Earning Date | 04-17-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.48 |
| 52 Week High | $20.44 | $2.24 |
| Indicator | TURB | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 48.75 |
| Support Level | $1.44 | $0.55 |
| Resistance Level | $2.02 | $0.60 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 60.61 | 53.66 |
Turbo Energy SA is an integrator of AI-driven energy storage and intelligent energy management solutions focused on transforming how energy is generated, stored, optimized, and consumed across residential, commercial, industrial, and utility-scale applications. It operates at the intersection of renewable energy infrastructure, energy storage, and software-driven optimization, combining battery systems, solar integration, and proprietary Artificial Intelligence (AI) technologies into unified intelligent energy platforms. Its solutions are designed to help customers reduce energy costs, improve operational resilience, increase energy independence, and optimize energy performance in increasingly decentralized and volatile energy markets. It generates the majority of its revenue from Spain.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.